AZ191

Item no.	HY-12277-25mg
Manufacturer	MedChem Express
CASRN	1594092-37-1
Amount	25 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Ashford AL, et al. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem J. 2014 Jan 1;457(1):43-56.\|[2]Chen H, et al. Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. Oncotarget. 2017 Nov 28;9(17):13154-13166.
Smiles	CN1C2=CN=CC=C2C(C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4OC)=NC=C3)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Product Description	AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 30 mg/mL
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported
Isoform	DYRK1
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.